5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems

      research-article
      1 , , 2 , 3 , 1 , 2 , 3 , 4 , 1 , 1 , 2 , 5 , 2 , 2 , 2 , 3 , 6 , 6 , 6 , 6 , 7 , 6 , 6 , 8 , 8 , 2 , 3 , 2 , 2 , 9 , 1 , 1 , 4 , 10 , , 2 , 3 ,
      Scientific Reports
      Nature Publishing Group UK
      RNA sequencing, Pancreatic cancer, Tumour heterogeneity, Functional clustering

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all common cancers. However, divergent outcomes exist between patients, suggesting distinct underlying tumor biology. Here, we delineated this heterogeneity, compared interconnectivity between classification systems, and experimentally addressed the tumor biology that drives poor outcome. RNA-sequencing of 90 resected specimens and unsupervised classification revealed four subgroups associated with distinct outcomes. The worst-prognosis subtype was characterized by mesenchymal gene signatures. Comparative (network) analysis showed high interconnectivity with previously identified classification schemes and high robustness of the mesenchymal subtype. From species-specific transcript analysis of matching patient-derived xenografts we constructed dedicated classifiers for experimental models. Detailed assessments of tumor growth in subtyped experimental models revealed that a highly invasive growth pattern of mesenchymal subtype tumor cells is responsible for its poor outcome. Concluding, by developing a classification system tailored to experimental models, we have uncovered subtype-specific biology that should be further explored to improve treatment of a group of PDAC patients that currently has little therapeutic benefit from surgical treatment.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

          Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here, we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, which includes primary, metastatic, and normal samples. By digitally separating tumor, stroma, and normal gene expression, we have identified and validated two tumor-specific subtypes including a “basal-like” subtype which has worse outcome, and is molecularly similar to basal tumors in bladder and breast cancer. Furthermore, we define “normal” and “activated” stromal subtypes which are independently prognostic. Our results provide new insight into the molecular composition of PDAC which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies is critical.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

            (2017)
            We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia.

              The precise details of pancreatic ductal adenocarcinoma (PDAC) pathogenesis are still insufficiently known, requiring the use of high-throughput methods. However, PDAC is especially difficult to study using microarrays due to its strong desmoplastic reaction, which involves a hyperproliferating stroma that effectively "masks" the contribution of the minoritary neoplastic epithelial cells. Thus it is not clear which of the genes that have been found differentially expressed between normal and whole tumor tissues are due to the tumor epithelia and which simply reflect the differences in cellular composition. To address this problem, laser microdissection studies have been performed, but these have to deal with much smaller tissue sample quantities and therefore have significantly higher experimental noise. In this paper we combine our own large sample whole-tissue study with a previously published smaller sample microdissection study by Grützmann et al. to identify the genes that are specifically overexpressed in PDAC tumor epithelia. The overlap of this list of genes with other microarray studies of pancreatic cancer as well as with the published literature is impressive. Moreover, we find a number of genes whose over-expression appears to be inversely correlated with patient survival: keratin 7, laminin gamma 2, stratifin, platelet phosphofructokinase, annexin A2, MAP4K4 and OACT2 (MBOAT2), which are all specifically upregulated in the neoplastic epithelia, rather than the tumor stroma. We improve on other microarray studies of PDAC by putting together the higher statistical power due to a larger number of samples with information about cell-type specific expression and patient survival.
                Bookmark

                Author and article information

                Contributors
                f.dijk@amsterdamumc.nl
                xin.wang@cityu.edu.hk
                m.f.bijlsma@amsterdamumc.nl
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                15 January 2020
                15 January 2020
                2020
                : 10
                : 337
                Affiliations
                [1 ]ISNI 0000000084992262, GRID grid.7177.6, Department of Pathology, Amsterdam UMC, , University of Amsterdam and Cancer Center Amsterdam, ; Amsterdam, Netherlands
                [2 ]ISNI 0000000084992262, GRID grid.7177.6, Laboratory for Experimental Oncology and Radiobiology, Amsterdam UMC, , University of Amsterdam and Cancer Center Amsterdam, ; Amsterdam, Netherlands
                [3 ]GRID grid.499559.d, Oncode Institute, ; Amsterdam, the Netherlands
                [4 ]ISNI 0000 0004 1792 6846, GRID grid.35030.35, Department of Biomedical Sciences, , City University of Hong Kong, ; Kowloon Tong, Hong Kong
                [5 ]ISNI 0000 0001 2171 9952, GRID grid.51462.34, Present Address: Cell Biology Program, Memorial Sloan Kettering Cancer Center, ; New York, United States of America
                [6 ]ISNI 0000000084992262, GRID grid.7177.6, Department of Surgery, Amsterdam UMC, , University of Amsterdam and Cancer Center Amsterdam, ; Amsterdam, Netherlands
                [7 ]ISNI 0000000089452978, GRID grid.10419.3d, Present Address: Department of Surgery, , Leiden University Medical Centre, ; Leiden, The Netherlands
                [8 ]ISNI 0000000084992262, GRID grid.7177.6, Department of Medical Oncology, Amsterdam UMC, , University of Amsterdam and Cancer Center Amsterdam, ; Amsterdam, Netherlands
                [9 ]ISNI 0000000084992262, GRID grid.7177.6, Department of Oncogenomics, Amsterdam UMC, , University of Amsterdam and Cancer Center Amsterdam, ; Amsterdam, Netherlands
                [10 ]ISNI 0000 0004 1792 6846, GRID grid.35030.35, Shenzhen Research Institute, , City University of Hong Kong, ; Shenzhen, China
                Author information
                http://orcid.org/0000-0003-3970-6601
                http://orcid.org/0000-0001-8509-0006
                http://orcid.org/0000-0002-5122-2418
                Article
                56826
                10.1038/s41598-019-56826-9
                6962149
                31941932
                9f7b75a6-3923-4b2f-a015-1cf64fe1c949
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 July 2019
                : 17 December 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100002920, Research Grants Council, University Grants Committee (RGC, UGC);
                Award ID: CityU 11102317
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                rna sequencing,pancreatic cancer,tumour heterogeneity,functional clustering
                Uncategorized
                rna sequencing, pancreatic cancer, tumour heterogeneity, functional clustering

                Comments

                Comment on this article